CR20220326A - Inhibidores de la proteína leucemia once-diecinueve (enl)/af9 yeats - Google Patents
Inhibidores de la proteína leucemia once-diecinueve (enl)/af9 yeatsInfo
- Publication number
- CR20220326A CR20220326A CR20220326A CR20220326A CR20220326A CR 20220326 A CR20220326 A CR 20220326A CR 20220326 A CR20220326 A CR 20220326A CR 20220326 A CR20220326 A CR 20220326A CR 20220326 A CR20220326 A CR 20220326A
- Authority
- CR
- Costa Rica
- Prior art keywords
- yeats
- enl
- inhibitors
- useful
- treating leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949160P | 2019-12-17 | 2019-12-17 | |
| PCT/US2020/065593 WO2021127166A1 (en) | 2019-12-17 | 2020-12-17 | Inhibitors of enl/af9 yeats |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220326A true CR20220326A (es) | 2023-02-10 |
Family
ID=76476792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220326A CR20220326A (es) | 2019-12-17 | 2020-12-17 | Inhibidores de la proteína leucemia once-diecinueve (enl)/af9 yeats |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518824A (ja) | 2021-05-13 | 2024-05-07 | ブリッジ メディシンズ | Ｅｎｌ／ａｆ９ ｙｅａｔｓのｃ結合阻害剤 |
| CN117580944A (zh) * | 2021-08-03 | 2024-02-20 | 苏州沙砾生物科技有限公司 | 一种修饰的免疫细胞及其用途 |
| US20250376473A1 (en) * | 2022-07-01 | 2025-12-11 | Cytosinlab Therapeutics Co., Ltd. | Prmts inhibitor and use thereof |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| US20260078121A1 (en) * | 2022-09-08 | 2026-03-19 | Bridge Medicines | Inhibitors of enl/af9 yeats and flt3 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2375359C2 (ru) * | 2004-09-03 | 2009-12-10 | Юхан Корпорейшн | ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-c]ПИРИДИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| US20110015225A1 (en) * | 2008-04-01 | 2011-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2522657B1 (en) * | 2010-01-06 | 2016-08-03 | Takeda Pharmaceutical Company Limited | Indole derivative |
| EP2818472A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
| WO2022146920A1 (en) * | 2020-12-28 | 2022-07-07 | Celgene Corporation | Heterocyclic compounds and their use for parasitic diseases |
| JP2024518824A (ja) * | 2021-05-13 | 2024-05-07 | ブリッジ メディシンズ | Ｅｎｌ／ａｆ９ ｙｅａｔｓのｃ結合阻害剤 |
-
2020
- 2020-12-17 CR CR20220326A patent/CR20220326A/es unknown
- 2020-12-17 AU AU2020407589A patent/AU2020407589A1/en active Pending
- 2020-12-17 JP JP2022538193A patent/JP7840851B2/ja active Active
- 2020-12-17 WO PCT/US2020/065593 patent/WO2021127166A1/en not_active Ceased
- 2020-12-17 US US17/757,492 patent/US20230027198A1/en active Pending
- 2020-12-17 EP EP20903540.1A patent/EP4076440B1/en active Active
- 2020-12-17 CA CA3162253A patent/CA3162253A1/en active Pending
- 2020-12-17 IL IL293839A patent/IL293839A/en unknown
- 2020-12-17 BR BR112022012273A patent/BR112022012273A2/pt unknown
- 2020-12-17 KR KR1020227024539A patent/KR20220129554A/ko active Pending
- 2020-12-17 CN CN202510375451.1A patent/CN120289456A/zh active Pending
- 2020-12-17 PH PH1/2022/551529A patent/PH12022551529A1/en unknown
- 2020-12-17 MX MX2022007442A patent/MX2022007442A/es unknown
- 2020-12-17 CN CN202080096854.8A patent/CN115427035B/zh active Active
-
2022
- 2022-07-13 CO CONC2022/0009852A patent/CO2022009852A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023527487A (ja) | 2023-06-29 |
| CA3162253A1 (en) | 2021-06-24 |
| JP7840851B2 (ja) | 2026-04-06 |
| CN115427035B (zh) | 2025-04-22 |
| CO2022009852A2 (es) | 2022-10-11 |
| MX2022007442A (es) | 2023-02-13 |
| EP4076440A1 (en) | 2022-10-26 |
| US20230027198A1 (en) | 2023-01-26 |
| EP4076440B1 (en) | 2026-07-08 |
| IL293839A (en) | 2022-08-01 |
| KR20220129554A (ko) | 2022-09-23 |
| PH12022551529A1 (en) | 2024-02-05 |
| CN115427035A (zh) | 2022-12-02 |
| WO2021127166A1 (en) | 2021-06-24 |
| AU2020407589A1 (en) | 2022-07-21 |
| EP4076440A4 (en) | 2023-11-08 |
| CN120289456A (zh) | 2025-07-11 |
| BR112022012273A2 (pt) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025003445A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38) | |
| MX2025001648A (es) | Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras) | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| MX2025015367A (es) | Inhibidores del oncogen del sarcoma de rata de kirsten (kras) | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| IL287838A (en) | Kras inhibitor dosage for cancer treatment | |
| CY1123561T1 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| PH12020500655A1 (en) | Compounds | |
| MY205856A (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| MX2021003559A (es) | Inhibidores de vap-1. | |
| JOP20220042A1 (ar) | طرق لعلاج فرط فينيل ألانين الدم | |
| MY203303A (en) | Compounds | |
| GEAP202014670A (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| CA185542S (en) | Table | |
| PH12019500070A1 (en) | Uses of indolinone compounds | |
| EP4616910A3 (en) | Pcna inhibitors | |
| CL2024001535A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| PH12022551529A1 (en) | Inhibitors of enl/af9 yeats | |
| MX2020010116A (es) | Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). | |
| ZA201904533B (en) | Antibodies against lif and uses thereof | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| AU2019251289A8 (en) | Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof |